Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding

Morgan, Clare; Jolles, Stephen; Ponsford, Mark J.; Evans, K. T.; Carne, Emily

doi:10.1097/aci.0000000000000864

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Self-infusing SCIg users play a more active role in their treatment compared with their IVIg counterparts, giving them the feeling of empowerment [41][42][43][44]. Indeed, patient preference assessments highlight the importance of continually offering patients information and a choice of IgRT infusion options [30][31][32].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, favorable patient perceptions of SCIg infusion satisfaction have been partly also based on association with better training experience, infusion efficiency, age, and longer treatment experience, highlighting the importance of accompanying patient education [30]. In general, patient preference assessments have highlighted the importance of continually offering patients information and a choice of IgRT infusion options; in addition to training, clinical support, and shared decision making, even if patients have been satisfied on one type of IgRT infusion method for many years [30][31][32].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Mallick

Solomon²,

Bassett³

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background Understanding the impact of different immunoglobulin (Ig) infusion methods (intravenous [IVIg] and subcutaneous [SCIg]) upon treatment experience can potentially facilitate optimization of patient outcomes. Here, the perspective of patients with primary and secondary immunodeficiency diseases (PID and SID, respectively) receiving IVIg and SCIg was evaluated, in terms of treatment satisfaction, accounting for treatment history, using Association des Patients Immunodéficients du Québec (APIQ) survey data. Methods The online APIQ survey (shared October 2020–March 2021) of patients with immunodeficiencies in Canada contained 101 questions on: Ig use, history, and detailed infusion characteristics; as well as structured patient-reported outcomes such as treatment satisfaction (via TSQM-9), symptom state (via PASS), general health perception (via GHP), and physical and mental function (via PROMIS). Adult respondents (≥ 18 years old) currently using Ig were compared by their current Ig infusion method (IVIg or SCIg cohort) overall, and in a sub-analysis, the IVIg cohort was compared with the SCIg cohort after stratification by respondents who started SCIg when naïve to Ig (‘SCIg naïve’) or with previous IVIg experience (‘SCIg switch’). Results In total, 54 respondents currently used IVIg and 242 used SCIg. The average duration per infusion of a weekly SCIg infusion was significantly shorter compared with the average duration of a 3–4 weekly IVIg infusion (p < 0.001). The SCIg cohort was associated with significantly higher scores for the TSQM-9 effectiveness domain compared with the IVIg cohort. The scores for TSQM-9 convenience and global satisfaction domains were similar in the two cohorts. The SCIg cohort was also associated with a significantly higher proportion of respondents who were in an acceptable symptom state and a lower proportion who reported very poor or poor perception of health compared with the IVIg cohort. Further, the SCIg naïve subgroup was associated with significantly higher TSQM-9 effectiveness and convenience domain scores compared with the IVIg cohort, while there was no significant difference between the SCIg switch subgroup and the IVIg cohort in terms of convenience. Conclusions A better understanding of how different IgRT administration methods impact treatment experience and satisfaction may assist with informed treatment decision making and ultimately further improvements in patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Mallick

Solomon²,

Bassett³

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Patients on intravenous biologicals or intravenous immunoglobulins also needed adjustments to their treatment regimes when infusion centers or hospitals were locked down. Rapid transitions from intravenous to subcutaneous products or self-injectables have been described with the use of subcutaneous immunoglobulins for antibody deficiency patients converted from intravenous immunoglobulin replacement [ 44 ], and subcutaneous infliximab for rheumatoid arthritis and inflammatory bowel disease patients converted from intravenous infliximab [ 45 ].…”

Section: Impact On Access To Allergy/immunology Servicesmentioning

confidence: 99%

COVID-19 in the Asia Pacific: impact on climate change, allergic diseases and One Health

Pawankar

Thong

Recto

et al. 2023

Asia Pacific Allergy

View full text Add to dashboard Cite

Climate change and environmental factors such as air pollution and loss of biodiversity are known to have a major impact not only on allergic diseases but also on many noncommunicable diseases. Coronavirus disease 2019 (COVID-19) resulted in many environmental changes during the different phases of the pandemic. The use of face masks, enhanced hand hygiene with hand rubs and sanitizers, use of personal protective equipment (gowns and gloves), and safe-distancing measures, reduced the overall incidence of respiratory infections and other communicable diseases. Lockdowns and border closures resulted in a significant reduction in vehicular traffic and hence environmental air pollution. Paradoxically, the use of personal protective equipment and disposables contributed to an increase in environmental waste disposal and new problems such as occupational dermatoses, especially among healthcare workers. Environmental changes and climate change over time may impact the exposome, genome, and microbiome, with the potential for short- and long-term effects on the incidence and prevalence of the allergic disease. The constant use and access to mobile digital devices and technology disrupt work–life harmony and mental well-being. The complex interactions between the environment, genetics, immune, and neuroendocrine systems may have short- and long-term impact on the risk and development of allergic and immunologic diseases in the future.

show abstract

“…SCIG represent a growing trend for the IG market: the formulation being stable at room temperature, it can be administered at home, further reducing the costs and discomfort associated with PreEP. In addition, during the COVID-19 pandemic many hospital-based IVIG patients quickly transitioned to home-based self-administered SCIG [13] .…”

mentioning

confidence: 99%

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients

Focosi¹,

Franchini

2023

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding

Cited by 5 publications

References 25 publications

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes

COVID-19 in the Asia Pacific: impact on climate change, allergic diseases and One Health

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients

Contact Info

Product

Resources

About